-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Hepatitis C are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Hepatitis C.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P, Latino Study Group
(2009) N Engl J Med 360: 257-67 - HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.
Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ
(2018) Cell Host Microbe 24: 703-716.e3 - Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.
Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE, Bjorkman PJ, Shaw GM, Bailey JR
(2018) Cell Host Microbe 24: 717-730.e5 - Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.
Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, Ikeda H, Shiina S, Kawabe T, Omata M
(2009) Hepatology 49: 1954-61 - Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.
Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M
(2009) Gut 58: 839-44 - Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L
(2015) J Hepatol 63: 1103-10 - Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.
Shimada M, Yoshida S, Masuzaki R, Schuppan D
(2012) J Hepatol 56: 299-300 - Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR
(2018) Proc Natl Acad Sci U S A 115: E82-E91 - Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients.
Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M
(2008) Clin Gastroenterol Hepatol 6: 459-64 - Co-infection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural China.
Qian HZ, Vermund SH, Kaslow RA, Coffey CS, Chamot E, Yang Z, Qiao X, Zhang Y, Shi X, Jiang Y, Shao Y, Wang N
(2006) AIDS 20: 1429-35 - An internationally generalizable risk index for mortality after one year of antiretroviral therapy.
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA
(2013) AIDS 27: 563-72 - Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients.
Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, Koike K
(2011) Int J Cancer 129: 2226-35 - Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.
Nakagawa H, Maeda S, Yoshida H, Tateishi R, Masuzaki R, Ohki T, Hayakawa Y, Kinoshita H, Yamakado M, Kato N, Shiina S, Omata M
(2009) Int J Cancer 125: 2264-9 - Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.
Lucas GM, Jing Y, Sulkowski M, Abraham AG, Estrella MM, Atta MG, Fine DM, Klein MB, Silverberg MJ, Gill MJ, Moore RD, Gebo KA, Sterling TR, Butt AA, NA-ACCORD of the IeDEA
(2013) J Infect Dis 208: 1240-9 - Hepatitis C virus infection in former commercial plasma/blood donors in rural Shanxi Province, China: the China Integrated Programs for Research on AIDS.
Qian HZ, Yang Z, Shi X, Gao J, Xu C, Wang L, Zhou K, Cui Y, Zheng X, Wu Z, Lu F, Lai S, Vermund SH, Shao Y, Wang N
(2005) J Infect Dis 192: 1694-700 - Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
Selitsky SR, Dinh TA, Toth CL, Kurtz CL, Honda M, Struck BR, Kaneko S, Vickers KC, Lemon SM, Sethupathy P
(2015) mBio 6: e01500-15 - A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy.
Fisher ME, Rossini M, Simmons E, Harris RC, Moeckel G, Zent R
(2004) Am J Kidney Dis 44: 567-73 - Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis.
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, Kitahata MM, Horberg MA, Brooks JT, Buchacz K, Rourke SB, Rachlis A, Napravnik S, Eron J, Willig JH, Moore R, Kirk GD, Bosch R, Rodriguez B, Hogg RS, Thorne J, Goedert JJ, Klein M, Gill J, Deeks S, Sterling TR, Anastos K, Gange SJ, NA-ACCORD and VACS Project Teams
(2013) J Acquir Immune Defic Syndr 62: 149-63 - Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte Ad, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA
(2015) J Acquir Immune Defic Syndr 69: 348-54 - Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C.
Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y
(2011) Cancer Epidemiol Biomarkers Prev 20: 2204-11 - Immunotherapy for HCV infection: next steps.
Lang K, Weiner DB
(2008) Expert Rev Vaccines 7: 915-23 - Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly.
Tejima K, Masuzaki R, Ikeda H, Yoshida H, Tateishi R, Sugioka Y, Kume Y, Okano T, Iwai T, Gotoh H, Katoh S, Suzuki A, Koike Y, Yatomi Y, Omata M, Koike K
(2010) J Gastroenterol 45: 876-84 - Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients.
Hikita H, Nakagawa H, Tateishi R, Masuzaki R, Enooku K, Yoshida H, Omata M, Soroida Y, Sato M, Gotoh H, Suzuki A, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H
(2013) J Gastroenterol 48: 366-73 - Treatment of glomerulonephritides associated with hepatitis C virus infection.
Giannico G, Manno C, Schena FP
(2000) Nephrol Dial Transplant 15 Suppl 8: 34-8 - Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography.
Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, Kato N, Kanai F, Sugioka Y, Ikeda H, Shiina S, Kawabe T, Omata M
(2008) J Clin Gastroenterol 42: 839-43 - Development of anti-factor XIII antibodies in a patient with hereditary factor XIII deficiency receiving therapy for chronic hepatitis C.
Sosa R, Gailani D, Neff AT
(2014) Haemophilia 20: e429-32 - Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros.
Masuzaki R, Yoshida H, Omata M
(2010) Dig Liver Dis 42 Suppl 3: S281-6 - Hepatocellular carcinoma in viral hepatitis: improving standard therapy.
Masuzaki R, Yoshida H, Tateishi R, Shiina S, Omata M
(2008) Best Pract Res Clin Gastroenterol 22: 1137-51 - Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver.
Lang Kuhs KA, Toporovski R, Ginsberg AA, Olsen AL, Shedlock DJ, Morrow MP, Yan J, Wells RG, Weiner DB
(2011) Hum Vaccin 7: 1326-35 - Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors.
Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M
(2010) J Viral Hepat 17: 91-7 - Autotaxin as a novel serum marker of liver fibrosis.
Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K, Yatomi Y
(2011) Clin Chim Acta 412: 1201-6 - Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME, TB Trials Consortium
(2015) Int J Tuberc Lung Dis 19: 1039-44, i-v - Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.
Masuzaki R, Tateishi R, Yoshida H, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Asaoka Y, Kondo Y, Goto T, Ikeda H, Shiina S, Omata M, Koike K
(2012) World J Gastroenterol 18: 1385-90 - Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors.
Ali SA, Donahue RM, Qureshi H, Vermund SH
(2009) Int J Infect Dis 13: 9-19 - Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan.
Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH
(2010) Int J Infect Dis 14 Suppl 3: e60-6
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
